Healthcare

Alzheimer’s Disease Drugs Market and Funding, and Pipeline Drugs Analysis to 2021

 

Summary

Latest Report Available at Analytical Research Cognizance, “Alzheimer’s Disease Drugs Market “provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

Description

Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer’s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Access The Complete report @ http://www.arcognizance.com/report/global-alzheimers-disease-drugs-market-regional-analysis-and-forecast-major-deals-and-funding-and-pipeline-drugs-analysis-to-2021

Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis

  • In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.
  • Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.
  • With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 – 2020.

Global Alzheimer’s Disease Country Wise Analysis

  • In the Alzheimer’s disease drugs market, the United States is the largest market.
  • Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.
  • China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.
  • The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.

Request for sample copy of  report @ http://www.arcognizance.com/enquiry-sample/89223

iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021” is a 189 Page report with 74 Figures and 14 Tables. This report provides a comprehensive assessment of the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease – Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market.

The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:

  1. Alzheimer’s Disease – Drugs Sales and Forecast
    2. Alzheimer’s Disease – Pipeline Drugs Sales Forecast
    3. Alzheimer’s Disease Drugs – Country Wise Market and Forecast
    4. Alzheimer’s Disease – Country Wise Prevalence and Forecast
    5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
    6. Alzheimer’s Disease – Major Deals in Alzheimer’s Drugs Market
    7. Alzheimer’s Disease – Funding in Alzheimer’s Disease Research
    8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges

The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:

  1. Exelon
    2. Razadyne/Reminyl
    3. Memary
    4. Ebixa
    5. Aricept
    6. Rivastach
    7. Namenda
    8. Nootropil
    9. Namzaric

Check Discount Offer Before Buying This Report @ http://www.arcognizance.com/discount/89223

The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:

  1. Gantenerumab
    2. Crenezumab
    3. Aducanumab

The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:

  1. United States
    2. France
    3. Germany
    4. Italy
    5. Spain
    6. United Kingdom
    7. Japan
    8. China
    9. India

List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development

  1. Phase I
    2. Phase II
    3. Phase III

The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:

  1. Strategic Alliance
    2. Licensing Agreement
    3. Collaboration Deals
    4. Mergers and Acquisitions

Data Source

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Some Points Of Table Of Content:

  1. Executive Summary
  2. Global Alzheimer’s Disease – Drugs Market and Prevalence Analysis
    2.1 Global Alzheimer’s Disease – Drugs Market and Forecast (2010 – 2021)
    2.2 Global Alzheimer’s Disease – Prevalence and Forecast (2010 – 2021)
  3. Global Alzheimer’s Disease – Country Wise Market Share and Forecast (2013 – 2021)
  4. Global Alzheimer’s Disease – Drugs Sales and Forecast To 2021
    4.1 Exelon (Rivastigmine) Sales and Forecast
    4.2 Razadyne/Reminyl Sales and Forecast
    4.3 Memary (Memantine) Sales and Forecast
    4.4 Ebixa (Memantine) Sales and Forecast
    4.5 Aricept (Donepezil) Sales and Forecast
    4.6 Rivastach Sales and Forecast
    4.7 Namenda (Memantine) Sales and Forecast
    4.8 Nootropil (Piracetam) Sales and Forecast
    4.9 Namzaric (Memantine and Donepezil) Sales and Forecast
  5. Global Alzheimer’s Disease – Pipeline Drugs Analysis and Sales Forecast
    5.1 Gantenerumab Drugs Analysis and Sales Forecast
    5.1.1 About Gantenerumab
    5.1.2 Clinical Trials
    5.1.3 Gantenerumab Drugs Sales Forecast
    5.2 Crenezumab Drugs Analysis and Sales Forecast
    5.2.1 About Crenezumab
    5.2.2 Clinical Trials
    5.2.3 Crenezumab Drugs Sales Forecast
    5.3 Aducanumab (BIIB037) Drugs Analysis and Sales Forecast
    5.3.1 About BIIB037
    5.3.2 Clinical Trials
    5.3.3 Aducanumab (BIIB037) Drugs Sales Forecast
  6. Alzheimer’s Disease Drugs Market and Prevalence – Country Wise Analysis
    6.1 United States – Alzheimer’s Disease Drugs Market and Prevalence Analysis
    6.1.1 United States – Alzheimer’s Disease Drugs Market and Forecast (2013 – 2021)
    6.1.2 United States – Alzheimer’s Disease Prevalence and Forecast (2010 – 2021)
    6.2 France – Alzheimer’s Disease Drugs Market and Prevalence Analysis
    6.2.1 France – Alzheimer’s Disease Drugs Market and Forecast (2013 – 2021)
    6.2.2 France – Alzheimer’s Disease Prevalence and Forecast (2012 – 2021)
    6.3 Germany – Alzheimer’s Disease Drugs Market and Prevalence Analysis
    6.3.1 Germany – Alzheimer’s Disease Drugs Market and Forecast (2013 – 2021)
    6.3.2 Germany – Alzheimer’s Disease Prevalence and Forecast (2012 – 2021)

…….

About Us:

http://arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics” based on the data collection facilities of big data, the face of “business research facilities” has changed drastically  . With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “out of the box” developments in the market.

Contact Us:

Matt Wilson,

100 Church street, 8th floor,

Manhattan, New york, 10007

Phone No: +1 (646) 434-7969

Email: [email protected]

Related Articles

Close